ReviewDrugs2016
Isavuconazole: A Review in Invasive Aspergillosis and Mucormycosis.
Review in Drugs, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Efficacy and safety of isavuconazole versus voriconazole for the treatment of invasive fungal infections: a meta-analysis with trial sequential analysis.BMC infectious diseases · 2025Pooled it
- Clinical research advances of isavuconazole in the treatment of invasive fungal diseases.Frontiers in cellular and infection microbiology · 2022Pooled it
- Meta-analysis of the safety of voriconazole in definitive, empirical, and prophylactic therapies for invasive fungal infections.BMC infectious diseases · 2017Pooled it
- An ortho-rhom-bic polymorph of isavuconazole.Acta crystallographica. Section E, Crystallographic communications · 2025Article
- Gastric Mucormycosis in a Critically Ill Patient Who Survived Without Surgery: A Case Report.Cureus · 2025Article
- Idiopathic aplastic anemia with concurrent complications of colonic perforation and mucormycosis: Case report.Heliyon · 2024Article
- Utility of Itraconazole in Combination with Liposomal Amphotericin B in Rhizopus oryzae Associated Mucormycosis-An Exploratory Study.Mycopathologia · 2024Article
- The efficacy and safety of first-line monotherapies in primary therapy of invasive aspergillosis: a systematic review.Frontiers in pharmacology · 2024Article
- The Fragile Patient: Considerations in the Management of Invasive Mould Infections (IMIs) in India.Cureus · 2023Review
- Post-COVID-19 Fungal Infection in the Aged Population.Vaccines · 2023Review
- COVID-19-Associated Pulmonary Mucormycosis.Journal of fungi (Basel, Switzerland) · 2022Review
- Pharmacokinetics of isavuconazole in healthy cats after oral and intravenous administration.Journal of veterinary internal medicine · 2022Article
- Mucormycosis: risk factors, diagnosis, treatments, and challenges during COVID-19 pandemic.Folia microbiologica · 2022Review
- Invasive Fungal Rhinosinusitis Due to Co-infection with Mucormycosis andClinical hematology international · 2022Article
- Coexistence of Mucormycosis and Granulomatosis With Polyangiitis: A Diagnostic and Therapeutic Challenge.Cureus · 2022Article
- Isavuconazole Treatment for Invasive Fungal Infections in Pediatric Patients.Pharmaceuticals (Basel, Switzerland) · 2022Article
- Real-World Use of Isavuconazole as Primary Therapy for Invasive Fungal Infections in High-Risk Patients with Hematologic Malignancy or Stem Cell Transplant.Journal of fungi (Basel, Switzerland) · 2022Article
- Population Pharmacokinetics and Pharmacodynamic Target Attainment of Isavuconazole againstPharmaceutics · 2021Article
- The Overview on the Pharmacokinetic and Pharmacodynamic Interactions of Triazoles.Pharmaceutics · 2021Review
- A Single-Center, Open-Label Trial of Isavuconazole Prophylaxis against Invasive Fungal Infection in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation.Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Isavuconazole is a second-generation triazole with activity against a broad spectrum of clinically important fungi. Its water-soluble prodrug, isavuconazonium sulfate (Cresemba
Indexed as
Identifiers
27766566What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.